Skip Navigation

JNCI Monographs 2001 2001(29):45-51;
© 2001 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Peterman, A.
Right arrow Articles by Yount, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Peterman, A.
Right arrow Articles by Yount, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute Monographs, No. 29, 45-51, 2001
© 2001 Oxford University Press

Mucositis in Head and Neck Cancer: Economic and Quality-of-Life Outcomes

Amy Peterman, David Cella, Gerald Glandon, Deborah Dobrez, Susan Yount

Affiliations of authors:A. Peterman, D. Cella, D. Dobrez, S. Yount, Northwestern University, Evanston, IL; G. Glandon, Univerity of Alabama, Birmingham.

Correspondence to:Amy Peterman, Ph.D., Center on Outcomes, Research and Education, 1000 Central St., Suite 101, Evanston, IL 60201 (e-mail: a-peterman{at}northwestern.edu).

Outcomes research typically assesses three major health care outcomes, including quantity of life, quality of life (QOL), and health care cost. This article highlights the impact of treatment-associated mucositis on health care costs and QOL. After a background description of the economic analyses of overall cancer treatment costs and of the incremental costs associated with other treatment side effects, data from a retrospective study of mucositis-specific costs are presented. The second half of this article reviews current knowledge about the effect that mucositis has on QOL. Because the empirical work that specifically evaluates mucositis and QOL is quite limited, studies examining proxies for mucositis grading are described. These include studies comparing the QOL of patients currently undergoing treatment, in which symptoms likely to be associated with mucositis are worse, with that of patients who have completed treatment. Also discussed are investigations examining both the relationship between specific mucositis-associated symptoms, such as pain and difficulty swallowing, and QOL and the weighting of different domains of mucositis-associated problems. Finally, several future research directions are suggested, with the intent of expanding knowledge about the economic and QOL impact of mucositis in patients treated for head and neck cancer. [J Natl Cancer Inst Monogr 2001;29:45–51]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
D. M. Brizel, B. A. Murphy, D. I. Rosenthal, K. J. Pandya, S. Gluck, H. E. Brizel, R. F. Meredith, D. Berger, M.-G. Chen, and W. Mendenhall
Phase II Study of Palifermin and Concurrent Chemoradiation in Head and Neck Squamous Cell Carcinoma
J. Clin. Oncol., May 20, 2008; 26(15): 2489 - 2496.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
N. Blijlevens, M. Schwenkglenks, P. Bacon, A. D'Addio, H. Einsele, J. Maertens, D. Niederwieser, W. Rabitsch, A. Roosaar, T. Ruutu, et al.
Prospective Oral Mucositis Audit: Oral Mucositis in Patients Receiving High-Dose Melphalan or BEAM Conditioning Chemotherapy--European Blood and Marrow Transplantation Mucositis Advisory Group
J. Clin. Oncol., March 20, 2008; 26(9): 1519 - 1525.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
N Blijlevens and S Sonis
Palifermin (recombinant keratinocyte growth factor-1): a pleiotropic growth factor with multiple biological activities in preventing chemotherapy- and radiotherapy-induced mucositis
Ann. Onc., May 1, 2007; 18(5): 817 - 826.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.